Insider Trading Activity Calithera Biosciences, Inc. (NASDAQ:CALA) – VP Sold 2,120 shares of Stock

Insider Trading Activity For Calithera Biosciences, Inc. (NASDAQ:CALA)

Story continues below

Keith Orford , VP of Calithera Biosciences, Inc. (NASDAQ:CALA) reportedly Sold 2,120 shares of the company’s stock at an average price of 18.31 for a total transaction amount of $38,817.20 SEC Form

Insider Trading History For Calithera Biosciences, Inc. (NASDAQ:CALA)

  • On 10/1/2014 Adage Capital Partners Gp Llc, Major Shareholder, bought 800,000 with an average share price of $10.00 per share and the total transaction amounting to $8,000,000.00.View SEC Filing
  • On 10/7/2014 Morgenthaler Venture Partners, Major Shareholder, bought 350,000 with an average share price of $10.00 per share and the total transaction amounting to $3,500,000.00.View SEC Filing
  • On 10/7/2014 Jean George, Director, bought 300,000 with an average share price of $10.00 per share and the total transaction amounting to $3,000,000.00.View SEC Filing
  • On 10/15/2014 Adage Capital Partners Gp Llc, Major Shareholder, bought 181,700 with an average share price of $6.96 per share and the total transaction amounting to $1,264,632.00.View SEC Filing
  • On 8/28/2015 Adage Capital Partners Gp Llc, Major Shareholder, bought 172,126 with an average share price of $5.27 per share and the total transaction amounting to $907,104.02.View SEC Filing
  • On 9/4/2015 Adage Capital Partners Gp Llc, Major Shareholder, bought 90,300 with an average share price of $5.93 per share and the total transaction amounting to $535,479.00.View SEC Filing
  • On 9/23/2015 Adage Capital Partners Gp Llc, Major Shareholder, bought 106,968 with an average share price of $6.03 per share and the total transaction amounting to $645,017.04.View SEC Filing
  • Analyst Ratings For Calithera Biosciences, Inc. (NASDAQ:CALA)
    These are 1 Hold Rating, 4 Buy Ratings .
    The current consensus rating for Calithera Biosciences, Inc. (NASDAQ:CALA) is Buy (Score: 2.80) with a consensus target price of $14.40 , a potential (11.66% downside)

    Analyst Ratings History For Calithera Biosciences, Inc. (NASDAQ:CALA)

    • On 3/9/2016 JPMorgan Chase & Co. Lower Price Target of rating Market Outperform with a price target of $20.00 to $12.00
    • On 1/24/2017 Citigroup Inc. Upgraded rating Sell to Neutral with a price target of $5.00
    • On 3/28/2017 JMP Securities Reiterated Rating Outperform with a price target of $12.00 to $12.00
    • On 4/3/2017 Leerink Swann Reiterated Rating Outperform to Outperform with a price target of $16.00
    • On 6/6/2017 Wells Fargo & Company Reiterated Rating Outperform with a price target of $15.00 to $20.00
    • On 6/12/2017 HC Wainwright Reiterated Rating Buy with a price target of $14.00 to $19.00

    Recent Trading Activity for Calithera Biosciences, Inc. (NASDAQ:CALA)
    Shares of Calithera Biosciences, Inc. closed the previous trading session at 16.30 down -1.10 -6.32% with 766,610 shares trading hands.

    An ad to help with our costs